Found: 5
Select item for more details and to access through your institution.
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.
- Published in:
- BioDrugs, 2015, v. 29, n. 4, p. 215, doi. 10.1007/s40259-015-0133-6
- By:
- Publication type:
- Article
Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.
- Published in:
- BioDrugs, 2015, v. 29, n. 4, p. 241, doi. 10.1007/s40259-015-0134-5
- By:
- Publication type:
- Article
Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.
- Published in:
- BioDrugs, 2015, v. 29, n. 4, p. 259, doi. 10.1007/s40259-015-0135-4
- By:
- Publication type:
- Article
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
- Published in:
- BioDrugs, 2015, v. 29, n. 4, p. 285, doi. 10.1007/s40259-015-0136-3
- By:
- Publication type:
- Article
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
- Published in:
- BioDrugs, 2015, v. 29, n. 4, p. 275, doi. 10.1007/s40259-015-0132-7
- By:
- Publication type:
- Article